Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

Is It Time To Revisit Boston Scientific (BSX) After This Yearโ€™s Sharp Share Price Pullback

AI-generated analysis

๐Ÿ“‰ Boston Scientific (BSX) shares have dropped 34.7% year-to-date and are currently trading around $61.86 per share.

๐Ÿ“Š Over the past year, the stock has declined 31.8%, though it delivered positive 3-year (21.9%) and 5-year (57.0%) returns.

๐Ÿ’ฐ A Discounted Cash Flow model projects an intrinsic value of approximately $112.50 per share, implying a 45% discount to the current price.

๐Ÿ” The company's latest twelve-month free cash flow was $3.63 billion, with estimates suggesting $6.84 billion in 2029.

๐Ÿ“ˆ Boston Scientific trades at a P/E ratio of 31.7x, which is higher than the medical equipment industry average of 26.7x but lower than its peer group average of 40.9x.

โš–๏ธ Simply Wall St's proprietary "Fair Ratio" for the company is set at 35.8x, indicating the stock trades below this tailored valuation estimate.

๐Ÿง  The article highlights that different investor narratives might result in varying fair value targets, such as $80 or $124 per share.

๐Ÿ“ข This analysis is based on historical data and analyst forecasts, with a disclaimer stating it does not constitute financial advice or a recommendation to buy or sell.

๐Ÿฅ Boston Scientific's strong position in the medical device space is being weighed against current market sentiment and healthcare trends.

Bullish Signals
  • Boston Scientific trades at an estimated intrinsic value of $112.50 per share according to the Discounted Cash Flow model, representing a 45.0% discount compared to its recent price of $61.86.
  • The company's proprietary 'Fair Ratio' of 35.8x suggests it is trading below its tailored valuation estimate given its earnings growth and risk profile.
  • Long-term free cash flow projections extend out to 2035 with extrapolated estimates suggesting $6.84b in cash flow by 2029, indicating strong future generating capacity.
  • Simply Wall St assigns a 5 out of 6 score on its value checks, highlighting positive fundamental metrics despite recent share price declines.
  • The current P/E ratio of 31.7x is below the peer group average of 40.9x, suggesting Boston Scientific may be relatively cheaper than some direct competitors.
Risk Factors
  • The stock has declined 34.7% year to date and 31.8% over the last year, indicating significant recent price weakness.
  • Current P/E of 31.7x sits above the Medical Equipment industry average of 26.7x, suggesting the stock appears expensive relative to sector peers despite being below the wider peer group average.
  • Valuation estimates vary significantly within investor community narratives, with fair value projections ranging from US$80 to US$124 per share, reflecting substantial uncertainty around intrinsic value.
  • The article explicitly states that analysis may not factor in the latest price-sensitive company announcements or qualitative material, potentially overlooking key negative catalysts.
Full Analysis
Boston Scientific (BSX) has experienced a significant share price decline over the past year, dropping approximately 31.8% from its previous high, with more recent drops of 34.7% year to date and 13.3% in the last month. Despite this sharp pullback, some investors are reassessing the stock's attractiveness at a current share price around US$61.86. The analysis highlights a divergence between short-term market sentiment and long-term valuation metrics, noting that while the stock has underperformed peers recently, historical 3 and 5-year returns remain positive at 21.9% and 57.0%, respectively. Recent coverage suggests the price drop is being weighed against broader healthcare trends and investor concerns regarding whether current prices reflect the company's position in the medical device space. A Discounted Cash Flow (DCF) model conducted by Simply Wall St indicates that Boston Scientific may be undervalued, projecting an intrinsic value of approximately US$112.50 per share based on a 2 Stage Free Cash Flow to Equity model using inputs such as recent free cash flow of $3.63 billion and estimates reaching $6.84 billion by 2029. This projection implies a potential 45.0% discount compared to the current market price, suggesting the stock trades well below this calculated modelled value. The analysis also evaluates traditional metrics like Price-to-Earnings (P/E) ratios, where Boston Scientific currently trades at 31.7x, which is higher than the Medical Equipment industry average of 26.7x but lower than its peer group average of 40.9x, positioning it as more affordable relative to some direct competitors. To further assess fair value, Simply Wall St employs a proprietary "Fair Ratio" methodology, estimating a reasonable P/E of 35.8x tailored to Boston Scientific's specific profile including earnings growth and market cap. Since the current P/E of 31.7x is below this Fair Ratio, the stock appears to be trading below this adjusted estimate as well. Beyond quantitative models, the article notes that qualitative "Narratives" from the Simply Wall St Community offer alternative valuation perspectives, with community member estimates ranging from US$80 to US$124 per share, reflecting varying degrees of optimism about future revenue and earnings potential. Ultimately, while the company faces valuation questions and recent headwinds, fundamental analysis using multiple methods suggests Boston Scientific could be trading at a significant discount to its calculated fair value, though this commentary is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell the stock.